Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned an average rating of “Hold” from the ten research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $11.33.

Several brokerages have weighed in on ZNTL. Jefferies Financial Group reiterated a “hold” rating and issued a $6.00 price objective (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a research note on Tuesday, June 18th. Stifel Nicolaus cut their price target on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, June 18th. HC Wainwright reduced their price target on Zentalis Pharmaceuticals from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, June 18th. Oppenheimer dropped their price objective on Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, June 18th. Finally, UBS Group lowered Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $28.00 to $5.00 in a report on Thursday, June 20th.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, insider Diana Hausman sold 3,356 shares of Zentalis Pharmaceuticals stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $12.62, for a total value of $42,352.72. Following the transaction, the insider now owns 373,876 shares in the company, valued at $4,718,315.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Diana Hausman sold 3,356 shares of the stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $12.62, for a total value of $42,352.72. Following the completion of the transaction, the insider now owns 373,876 shares of the company’s stock, valued at approximately $4,718,315.12. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Cam Gallagher sold 9,597 shares of the business’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $11.98, for a total transaction of $114,972.06. Following the sale, the chief financial officer now directly owns 633,680 shares in the company, valued at approximately $7,591,486.40. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ZNTL. Vanguard Group Inc. increased its position in Zentalis Pharmaceuticals by 6.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock valued at $105,047,000 after acquiring an additional 307,490 shares during the period. Rafferty Asset Management LLC increased its holdings in Zentalis Pharmaceuticals by 79.4% in the fourth quarter. Rafferty Asset Management LLC now owns 360,125 shares of the company’s stock valued at $5,456,000 after purchasing an additional 159,439 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals in the first quarter valued at $606,000. Tower Research Capital LLC TRC raised its position in Zentalis Pharmaceuticals by 252.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock worth $55,000 after purchasing an additional 2,589 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in Zentalis Pharmaceuticals during the 1st quarter worth about $680,000.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $3.89 on Friday. The stock has a 50 day simple moving average of $6.53 and a 200 day simple moving average of $10.87. Zentalis Pharmaceuticals has a 1-year low of $3.27 and a 1-year high of $29.03.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.91. The firm had revenue of $40.56 million for the quarter, compared to the consensus estimate of $35.00 million. During the same quarter in the previous year, the business earned ($1.07) EPS. On average, research analysts forecast that Zentalis Pharmaceuticals will post -2.72 earnings per share for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.